Who owns Keytruda patents in the real world?
Keytruda (pembrolizumab) is owned by the company that developed it: Merck & Co. (often referenced via MSD outside the U.S.). Merck & Co. is the patent holder for the pembrolizumab product and related rights tied to its development and commercialization.
Do biosimilars or competitors hold any related patents?
Competitors and biosimilar developers generally do not “own Keytruda patents” themselves. Instead, they may hold patents on their own molecules, manufacturing processes, or methods. Those other patents can matter for when products can enter markets, but they are separate from the patents held by Merck & Co. for Keytruda.
Can the patent portfolio be split between subsidiaries or licensees?
Yes. Patent ownership for large pharma products is often structured across corporate entities (subsidiaries/affiliates) and sometimes through licensing arrangements. But the core rights for Keytruda are tied to Merck & Co.’s ownership.
Where you can verify the patent holder for a specific country or patent number
To confirm the holder for a particular Keytruda patent (by jurisdiction), you typically need to look up:
- the patent number in the national/regional patent register (e.g., USPTO for U.S. patents, EPO/Espacenet for Europe), or
- the product’s patent lists compiled for that country (where available).
Those records show the named assignee (the legal patent holder) for each patent.
Sources
I don’t have the provided dataset or links needed to cite the exact patent assignee name(s) from a specific registry entry. If you share a country (e.g., U.S. or EU) or a patent number (or link), I can identify the exact named patent holder from that record.